Lung cancer screening program using low-dose tomography and metabolomic evaluation in a public service.

Study identifier:D5162R00036

ClinicalTrials.gov identifier:NCT06376097

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Implementation of a lung cancer screening program in a public service, using low-dose tomography and metabolomics evaluation

Medical condition

lung cancer

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

1000

Study type

Observational

Age

45 Years - 74 Years

Date

Study Start Date: 19 Apr 2023
Estimated Primary Completion Date: 28 Feb 2025
Estimated Study Completion Date: 28 Feb 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria